Skip to Main Content

Author Details

John Paul Shen
The University of Texas MD Anderson Cancer Center
2006
47
20
Trey Ideker (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36351210Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in <i>RAS/RAF</i> Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy.J Clin Oncol2023
37487150Transcriptional Profiling and Consensus Molecular Subtype Assignment to Understand Response and Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Colorectal Cancer.JCO Precis Oncol2023
37738316Taxane-Based Chemotherapy Is Effective in Metastatic Appendiceal Adenocarcinoma.Oncologist2023
37609177Impact of <i>KRAS</i> Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma.Res Sq2023
36993681Antitumor activity of intraperitoneal paclitaxel in orthotopic patient-derived xenograft models of mucinous appendiceal adenocarcinoma.bioRxiv2023
37433032Intraperitoneal Paclitaxel Is a Safe and Effective Therapeutic Strategy for Treating Mucinous Appendiceal Adenocarcinoma.Cancer Res2023
37261831Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial.JAMA Netw Open2023
36853519Prognostic significance of acellular mucin in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for appendiceal neoplasms.Langenbecks Arch Surg2023
36781990Survival improvement for patients with metastatic colorectal cancer over twenty years.NPJ Precis Oncol2023
35108036Clinical and Molecular Characterization of <i>POLE</i> Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers.JCO Precis Oncol2022
35508177Patient-derived micro-organospheres enable clinical precision oncology.Cell Stem Cell2022
35697807Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression.Nat Biotechnol2022
36239938Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer.JAMA Netw Open2022
36382087Bintrafusp alfa, an anti-PD-L1:TGF-β trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer.Cancer Res Commun2022
35879396Oncogene addiction to GNAS in GNAS<sup>R201</sup> mutant tumors.Oncogene2022
35307803What is the Risk for Peritoneal Metastases and Survival Afterwards in T4 Colon Cancers?Ann Surg Oncol2022
35022962Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective.Cancer Metastasis Rev2022
33414133ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer.Clin Cancer Res2021
34881776Artificial intelligence, molecular subtyping, biomarkers, and precision oncology.Emerg Top Life Sci2021
34378358Chromatin Remodeling of Colorectal Cancer Liver Metastasis is Mediated by an HGF-PU.1-DPP4 Axis.Adv Sci (Weinh)2021
34638407Implications of Intratumor Heterogeneity on Consensus Molecular Subtype (CMS) in Colorectal Cancer.Cancers (Basel)2021
34223192Few-shot learning creates predictive models of drug response that translate from high-throughput screens to individual patients.Nat Cancer2021
34250391Comprehensive Clinical and Molecular Characterization of <i>KRAS</i> <sup>G12C</sup>-Mutant Colorectal Cancer.JCO Precis Oncol2021
34367949The Provocative Roles of Platelets in Liver Disease and Cancer.Front Oncol2021
32545271Relative Abundance of SARS-CoV-2 Entry Genes in the Enterocytes of the Lower Gastrointestinal Tract.Genes (Basel)2020
33037839Regarding Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers.Oncologist2020
32733093Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer.Br J Cancer2020
30718357Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer.Cancer Res2019
31767022Lamotrigine-induced hemophagocytic lymphohistiocytosis with Takotsubo cardiomyopathy: a case report.J Med Case Rep2019
31602605Ultrahigh-Density Screens for Genome-Wide Yeast EMAPs in a Single Plate.Methods Mol Biol2019
29610481A global transcriptional network connecting noncoding mutations to changes in tumor gene expression.Nat Genet2018
32913983Genomic Landscape of Appendiceal Neoplasms.JCO Precis Oncol2018
32913982Genomic and Proteomic Alterations in Desmoplastic Small Round Blue-Cell Tumors.JCO Precis Oncol2018
29932943Synthetic Lethal Networks for Precision Oncology: Promises and Pitfalls.J Mol Biol2018
30297789Typing tumors using pathways selected by somatic evolution.Nat Commun2018
29636367Disruption of <i>NSD1</i> in Head and Neck Cancer Promotes Favorable Chemotherapeutic Responses Linked to Hypomethylation.Mol Cancer Ther2018
29186130Correcting CRISPR for copy number.Nat Genet2017
28481362Genetic interaction mapping in mammalian cells using CRISPR interference.Nat Methods2017
28319113Combinatorial CRISPR-Cas9 screens for de novo mapping of genetic interactions.Nat Methods2017
27096704Synthesis of Eupalinilide E, a Promoter of Human Hematopoietic Stem and Progenitor Cell Expansion.J Am Chem Soc2016
27453043A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy.Mol Cell2016
26083491ERCC1 and TS Expression as Prognostic and Predictive Biomarkers in Metastatic Colon Cancer.PLoS One2015
26437225Chemogenetic profiling identifies RAD17 as synthetically lethal with checkpoint kinase inhibition.Oncotarget2015
25086664Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss.Nat Genet2014
24037242Network-based stratification of tumor mutations.Nat Methods2013
20616024Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease.Proc Natl Acad Sci U S A2010
16720270A robust small-molecule microarray platform for screening cell lysates.Chem Biol2006
  • 1 - 47 of 47

Recommended Authors

Memorial Sloan Kettering Cancer Center
Career Start Year 2017
Number of shared co-authors 2
The University of Texas MD Anderson Cancer Center
Career Start Year 2014
Number of shared co-authors 13
University of Colorado Denver | Anschutz Medical Campus
Career Start Year 2013
Number of shared co-authors 0
Houston Methodist Hospital
Career Start Year 2012
Number of shared co-authors 1
Memorial Sloan Kettering Cancer Center
Career Start Year 2011
Number of shared co-authors 0
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 1
Queen's University Belfast
Career Start Year 2009
Number of shared co-authors 2
Dana-Farber Cancer Institute
Career Start Year 2009
Number of shared co-authors 15
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Career Start Year 2008
Number of shared co-authors 1
Princess Maxima Center for Pediatric Oncology
Career Start Year 2008
Number of shared co-authors 2
The University of Texas MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 13
Memorial Sloan Kettering Cancer Center
Career Start Year 2006
Number of shared co-authors 9
Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus
Career Start Year 2006
Number of shared co-authors 8
Institute of Pathology, University Hospital Heidelberg
Career Start Year 2005
Number of shared co-authors 3
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 17
Broad Institute of Harvard and MIT
Career Start Year 2004
Number of shared co-authors 5
Present Address: Tempus Labs Inc.
Career Start Year 2003
Number of shared co-authors 1
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2003
Number of shared co-authors 0
Huntsman Cancer Institute, The University of Utah
Career Start Year 2003
Number of shared co-authors 3
University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 18
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 11
The University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 13
Memorial Sloan Kettering Cancer Center
Career Start Year 2002
Number of shared co-authors 3
Uppsala University
Career Start Year 1999
Number of shared co-authors 1
University of California san francisco
Career Start Year 1999
Number of shared co-authors 10
Wellcome Sanger Institute
Career Start Year 1998
Number of shared co-authors 4
UF Health Cancer Center
Career Start Year 1998
Number of shared co-authors 11
Cleveland Clinic.
Career Start Year 1994
Number of shared co-authors 8
Wellcome Sanger Institute
Career Start Year 1993
Number of shared co-authors 8
Broad Institute of Harvard and MIT
Career Start Year 1991
Number of shared co-authors 14

Collaborators

University of California San Diego
Co-authored papers 15
University of Texas MD Anderson Cancer Center
Co-authored papers 14
University of California San Diego
Co-authored papers 6
The University of Texas MD Anderson Cancer Center
Co-authored papers 6
University of California
Co-authored papers 5
Illumina Inc.
Co-authored papers 5
University of California San Diego
Co-authored papers 4
The University of Texas MD Anderson Cancer Center
Co-authored papers 4
University of California San Diego
Co-authored papers 3
University of California San Diego
Co-authored papers 3
University of California San Diego
Co-authored papers 3
Broad Institute of Harvard and MIT
Co-authored papers 3
The University of Texas MD Anderson Cancer Center
Co-authored papers 3
The University of Texas MD Anderson Cancer Center
Co-authored papers 3
University of California
Co-authored papers 3
University of California San Diego
Co-authored papers 3
Broad Institute
Co-authored papers 2
University of California san francisco
Co-authored papers 2
University of the Sciences
Co-authored papers 2
St Jude Children's Research Hospital
Co-authored papers 2
Co-authored papers 2
University of Illinois
Co-authored papers 2
University of South Alabama
Co-authored papers 2
University of California San Diego, United States of America Moores Cancer Center
Co-authored papers 2
University of California San Diego
Co-authored papers 2
Amgen Inc.
Co-authored papers 2
Leiden University Medical Center
Co-authored papers 2
Stem Cell Program and Institute for Genomic Medicine, University of California
Co-authored papers 2
University of California San Francisco
Co-authored papers 2
University of Texas MD Anderson Cancer Center
Co-authored papers 2